Combined Oral Contraceptive Drug-Drug Interaction Study With Ganfeborole, a New Anti-Tuberculosis Agent - PubMed
4 days ago
- #tuberculosis
- #drug-drug interaction
- #pharmacokinetics
- Ganfeborole is a new anti-tuberculosis agent with bactericidal activity and good tolerability in clinical trials.
- A Phase 1 drug-drug interaction (DDI) study assessed ganfeborole's effect on the pharmacokinetics of ethinyl estradiol (EE) and levonorgestrel (LNG) in healthy women.
- Results showed no significant DDI for LNG parameters, but inconclusive results for EE AUC(0-inf).
- No treatment-related adverse events were reported, but further DDI assessments are warranted.
- Strict contraception requirements will be maintained in future trials involving ganfeborole.